Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.62 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.52 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752858 | 1.00 | CYSLTR2 (0.62) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL17907495 | 0.94 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL17907496 | 0.94 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL751930 | 0.91 | KDM4E (0.57) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL751929 | 0.91 | KDM4E (0.57) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL2840222 | 0.89 | KDM4E (0.59) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL2840220 | 0.89 | KDM4E (0.59) | CYSLTR2CYSLTR1KDM4EMAPTHSP90AA1 | |
| SCHEMBL17975277 | 0.83 | MAPT (0.67) | KDM4EMAPTHSP90AA1ALDH1A1NPSR1 | |
| SCHEMBL7508691 | 0.82 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1KDM4EALDH1A1APP | |
| SCHEMBL7508687 | 0.82 | CYSLTR2 (0.55) | CYSLTR2CYSLTR1KDM4EALDH1A1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-1422218-B1 | ANTIVIRAL AGENT | SHIONOGI & CO (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-2181985-A1 | Antiviral Agent | SHIONOGI & CO., LTD. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | CYSLTR2 3946/4885CYSLTR1 3127/4885KDM4E 336/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CYSLTR2 4226/4885CYSLTR1 3571/4885KDM4E 382/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CYSLTR2 4226/4885CYSLTR1 3571/4885KDM4E 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.